Biotechnology is evolving at an extraordinary pace. Scientific innovation continues to accelerate, commercial models are becoming more complex, and the expectations placed on commercial organizations continue to grow.
Yet one challenge remains remarkably consistent: hiring the right people.
Despite advances in executive search, behavioral interviewing, leadership assessments, and talent acquisition, biotechnology companies continue to make hiring decisions that significantly influence commercial performance, organizational culture, and ultimately, patient access to innovative therapies.
The challenge extends far beyond executive leadership.
It affects Commercial, Medical Affairs, Market Access, Marketing, Sales, Commercial Operations, Patient Services, Business Analytics, Training, Regulatory Affairs, and virtually every function responsible for bringing innovative therapies to patients.
The question is no longer whether talented people exist. The question is whether biotechnology companies are identifying the individuals who can build collaborative, high-performing organizations capable of successfully commercializing increasingly complex therapies.
Experience Is Only Part of the Story
Biotechnology has traditionally rewarded experience.
Candidates are evaluated based on previous company names, launch experience, years in rare disease, therapeutic expertise, titles, and the size of the organizations they have managed.
These qualifications certainly matter.
But they rarely tell the complete story.
Commercial success is almost never created by one individual. It is built by organizations that function exceptionally well together.
A candidate may have participated in a successful launch without being the reason it succeeded. Likewise, an outstanding leader may have worked in an organization that never reached its full potential because of factors beyond their control.
Resumes describe where someone has worked. They reveal far less about how someone works.
The Missing Interview Questions
Most biotechnology interviews focus heavily on accomplishments.
Far fewer explore the characteristics that determine long-term organizational success.
Questions such as these are often overlooked:
- How does this individual build trust across departments?
- How do they respond when challenged by colleagues?
- Can they influence without relying on authority?
- Do others genuinely want to work with them again?
- How do they develop the people around them?
- Have they consistently strengthened the organizations they joined?
- Are they known for solving problems or creating them?
These qualities rarely appear on a resume, yet they often determine whether commercialization succeeds.
Collaboration Has Become a Competitive Advantage
Commercialization today is far more complex than it was even a decade ago.
Clinical Development, Medical Affairs, Commercial, Marketing, Market Access, Regulatory Affairs, Patient Advocacy, Manufacturing, and Sales must function as one coordinated organization years before product approval.
Unfortunately, many companies still operate as independent departments with separate priorities.
Information moves slowly.
Problems remain inside functional silos.
Decisions become fragmented.
Departments sometimes measure their own success instead of the organization's success.
As therapies become more sophisticated, the organizations responsible for bringing them to patients must become equally sophisticated.
Medical Affairs: One of Biotechnology's Greatest Untapped Opportunities
Few functions better illustrate this challenge than Medical Affairs.
Medical Science Liaisons possess exceptional scientific expertise and maintain trusted relationships with academic physicians, investigators, and Centers of Excellence. Their field insights often provide the earliest understanding of changing treatment patterns, physician concerns, implementation barriers, and emerging clinical needs.
Scientific independence must always be protected.
Compliance is essential.
However, maintaining appropriate regulatory boundaries should not prevent thoughtful collaboration across the organization.
When Medical Affairs, Clinical Development, Commercial, Market Access, and Patient Advocacy appropriately share insights within established compliance standards, companies develop a far more complete understanding of physician needs, patient barriers, and opportunities to improve care.
The objective is not promotional influence. The objective is organizational alignment in service of better patient outcomes.
Hiring for Organizational Fit
Perhaps the greatest misconception in biotechnology hiring is that success automatically transfers from one company to another.
It doesn't.
A leader who thrives in a global pharmaceutical company may struggle within a forty-person biotechnology startup.
Someone who excels during a first commercial launch may not enjoy leading a mature brand.
Likewise, an experienced biotechnology executive may be an outstanding hire for one organization and a poor fit for another.
Hiring is not simply about identifying talented people.
It is about identifying talented people whose leadership style, communication, adaptability, emotional intelligence, and collaborative approach align with the organization's culture, stage of growth, and strategic objectives.
The best hire is not always the most experienced candidate. Often, it is the person who elevates everyone around them.
Looking Ahead
The biotechnology industry has never had access to more experienced professionals, more sophisticated recruiting firms, or more advanced hiring tools.
Yet hiring remains one of its greatest strategic risks.
The future will belong to organizations that look beyond resumes, titles, and past employers to understand how candidates think, collaborate, lead, and solve problems.
Scientific innovation will continue to transform medicine.
The organizations that succeed will recognize that commercial excellence depends on more than scientific expertise. It depends on building cultures where trust, accountability, collaboration, and execution are valued as highly as technical experience.
Because the therapies of the future will require organizations that are every bit as innovative as the science they are bringing to patients.
And that future begins with hiring.